


Diabetes Solutions

The prevalence of diabetes is expected to increase **51% in the next 26 years**, rising from 463 million people living with diabetes in 2019 to 700 million worldwide by 2045.* In today's increasingly complex drug development paradigm, new type 2 diabetes drugs will have to demonstrate a positive effect on cardiovascular and/or renal outcomes in order to succeed. Demonstrating benefits in additional indications like obesity, type 1 diabetes and NASH is potentially another way for type 2 diabetes drug manufacturers to differentiate their products. You need one global partner to support your diabetes research from discovery to post-market.

We offer central, bioanalytical, ADME and genomics labs, plus support for **companion diagnostic** studies for personalized medicine. Our suite of solutions includes:



With access to **7 College of American Pathologists (CAP)–accredited Central Laboratories**, our global logistics expertise minimizes shipping issues while meeting country-specific regulatory requirements and import/export licensing for specimen transport.

Learn more at www.Q2LabSolutions.com/central-laboratories.

We participate in many international proficiency and certification programs for endocrine testing such as:

- ✓ The National Glycohemoglobin Standardization Program (NGSP)
- ✓ CDC Lipid Standardization Program
- ✓ CAP Proficiency Scheme

And Q² Solutions is a member of the ADA, AACC, IFCC and IDF.



Q² Solutions provides support for the full spectrum of diabetic complications: cardiac and vascular pathology due to systemic inflammation; as well as, renal, retinal and neuropathies due to the interactions of numerous cytokines, chemokines and oxidative stress markers. Q² Solutions' diabetes experts work with pharmaceutical scientists to design and support the best panels of unique biomarkers for the diagnosis and treatment of these underserved complications.



Since 2011, Q² Solutions has provided clinical services for **>200**

diabetes studies involving **>135,000** patients in **69 countries** worldwide

Q² Solutions helped develop **95%**



of the Top 20 best-selling diabetes products of 2019

Our experience includes lab testing services in support of clinical trials for insulins, GLP-1/glucagon dual-agonists, SGLT2 inhibitors, DPP-4 inhibitors (gliptins), combination therapies and more. Since 2010, our experience has included **lab testing solutions** in support of:

34 clinical studies for **GLP-1/glucagon dual-agonists** **33** clinical studies for **DPP-4 inhibitors (gliptins)**
125 clinical studies for **insulins** **35** clinical studies for **SGLT2 inhibitors**

Our broad range of testing services and capabilities for diabetes includes:

- | | | |
|---|--|---|
| <ul style="list-style-type: none"> • 1,5-anhydroglucitol • Adiponectin • Apolipoproteins • C-Peptide • Calcitonin • Cystatin C • Free fatty acids (NEFA) • Fructosamine | <ul style="list-style-type: none"> • GAD antibodies • Glucagon • GLP-1 • Glycated albumin • Hemoglobin A1c • IA2 antibodies • Insulin/HOMA test • Insulin antibodies (IAA) | <ul style="list-style-type: none"> • Leptin • Microalbumin (ACR) • NTproBNP • Proinsulin, total and free • Zn transporter antibodies |
|---|--|---|

Q² Solutions has helped develop



of all metabolic disorder products approved since 2011 

 Q² Solutions has helped develop **90%** of 2019's top 50 best-selling drugs

Q² Solutions helped develop **65%** of all the cardiovascular products approved since 2011 



Put our expertise to work for your diabetes product development program. **Contact us today.**

* International Diabetes Federation. IDF Diabetes Atlas, 9th edn. Brussels, Belgium: 2019. Available at: <https://www.diabetesatlas.org>

Contact us

Toll free: 1 855.277.9929
Direct: +1 919.998.7000
International: +44 (0) 1506 814000
Website: www.Q2LabSolutions.com

